Share on StockTwits
 

AbbVie (NASDAQ:ABBV) is scheduled to be posting its quarterly earnings results on Friday, January 31st. Parties that are interested in registering for the company’s conference call can do so using this link.

AbbVie (NASDAQ:ABBV) opened at 47.61 on Thursday. AbbVie has a 52 week low of $35.01 and a 52 week high of $54.78. The stock has a 50-day moving average of $51.11 and a 200-day moving average of $47.39. The company has a market cap of $75.605 billion and a P/E ratio of 16.82.

A number of analysts have recently weighed in on ABBV shares. Analysts at BMO Capital Markets cut their price target on shares of AbbVie from $58.00 to $57.00 in a research note to investors on Tuesday. On a related note, analysts at Jefferies Group raised their price target on shares of AbbVie from $67.00 to $68.00 in a research note to investors on Thursday, January 9th. They now have a “buy” rating on the stock. Finally, analysts at UBS AG reiterated a “neutral” rating on shares of AbbVie in a research note to investors on Monday, January 6th. They now have a $56.00 price target on the stock, up previously from $46.00. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $55.88.

AbbVie Inc (NASDAQ:ABBV) is a research-based pharmaceuticals company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.